Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy
Mohammad H. Al-Shaer, Kelly Maguigan, Jennifer Ashton, Veena Venugopalan, Molly E. Droege, Carolyn D. Philpott, Christopher A. Droege, Daniel P. Healy, Eric W. Mueller, Charles A. Peloquin
Abstract
was 64% (0%-100%). The mortality rate was 53%. There was no difference in target attainment in terms of clinical cure and 30-day mortality. This model can be used as a precision dosing tool in CRRT patients. Future studies may address other PK/PD targets in a larger population.
Topics & Concepts
CefepimeRenal replacement therapyMedicineDosingIntensive care unitIntensive care medicinePopulationCritically illAcute kidney injuryTherapeutic drug monitoringKidney diseasePharmacokineticsIntensive careMortality ratePharmacodynamicsInternal medicineHemofiltrationAdverse effectAPACHE IIMechanical ventilationAnesthesiaAntibiotics Pharmacokinetics and EfficacyAcute Kidney Injury ResearchUrinary Tract Infections Management